Naveen L Pereira et al conducted a trial to assess the impact of a genotype-guided oral P2Y12 inhibitor strategy on ischemic outcomes among CYP2C19 loss-of-function (LOF) carriers following percutaneous coronary interventions (PCIs) in patients with coronary artery disease (CAD). The gene discussed is CYP2C19; the disease is coronary artery disorder.